Synonyms: compound I-30 [WO2021046407] | LY-3871801 | LY3871801 | R-552 | R552
Compound class:
Synthetic organic
Comment: The chemical structure for ocadusertib was obtained from WHO proposed INN list 131 (August 2024). The INN record describes the compound as a serine/threonine kinase inhibitor. A structure match in PubChem suggests that this is the INN for Eli Lilly/Rigel's clinical lead, RIPK1 inhibitor LY3871801, and confirmed by information provided on this pipeline page. Ocadusertib/LY3871801 is one of the structures claimed in patent WO2021046407A1 [1].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Chen Y, Yu J, Shaw S, Darwish I, Taylor V, Bhamidipati S, Luo Z, Kolluri K. (2021)
Rip1 inhibitory compounds and methods for making and using the same. Patent number: WO2021046407A1. Assignee: Rigel Pharmaceuticals, Inc.. Priority date: 04/09/2020. Publication date: 11/03/2021. |